OnBioVC

OptiMedica, Corp.: Series E $35M

arubenstein — Fri, 10 May 2013 07:00:01 +0000

OptiMedica (Sunnyvale, CA), a commercial-stage medical device company focused on laser technology for cataract surgery, closed a $35M Series E financing. Participants include Kleiner Perkins Caufield & Byers, Alloy Ventures, DAG Ventures, BlackRock Private Equity Partners and Bio*One Capital.

iRythm Technologies, Inc.: Series C $1.5M

arubenstein — Thu, 09 May 2013 07:00:02 +0000

iRhythm Technologies (San Francisco, CA), a commercial-stage medical device company that focused on cardiac rhythm monitoring, closed a $1.5M Series C financing. Participants include the California HealthCare Foundation.

Edison Pharmaceuticals, Inc.: Series F $20M

arubenstein — Wed, 08 May 2013 07:00:45 +0000

Edison Pharmaceuticals (Mountain View, CA), a clinical-stage pharmaceutical company developing small molecules to treat mitochondrial disease, closed a $20M Series F financing. Participants include Mitsui & Co. Global Investment.

New Haven Pharmaceuticals, Inc.: Series A $6.6M

arubenstein — Tue, 07 May 2013 03:46:24 +0000

New Haven Pharmaceuticals (New Haven, CT), a specialty pharmaceutical company focused on a slow release aspirin product, closed a $6.6M Series A. Participants include Connecticut Innovations and private investors.

Kiadis Pharma, B.V.: Series D $12.8M

arubenstein — Mon, 06 May 2013 04:13:31 +0000

Kiadis Pharma (Netherlands), a clinical-stage biopharmaceutical company developing treatments for blood cancers, closed a $12.8M Series D financing. Participants include Life Sciences Partners, DFJ-Esprit, Alta Partners, Quest for Growth and NOM.

Synovex Corporation: Series C $3.5M

arubenstein — Fri, 03 May 2013 07:00:51 +0000

Synovex (Boston, MA), a clinical stage biotechnology company focused on inhibiting the progression of fibrotic diseases such as arthritis, closed a $3.5M Series C financing. Participants were not identified.

Neurovance, Inc.: Series A $7M

arubenstein — Thu, 02 May 2013 07:00:15 +0000

Neurovance (Cambridge, MA), a clinical stage pharmaceutical company developing a norepinephrine, dopamine and serotonin triple uptake inhibitor to treat ADHD, closed a $7M Series A financing. Participants include Novartis Venture Fund and H&Q Life Sciences Investors.

Cebix, Inc.: Series B $30.9M

arubenstein — Thu, 02 May 2013 07:00:08 +0000

Cebix (San Diego, CA), a clinical stage biotechnology company developing a modified insulin C-peptide for the treatment of complications associated with diabetes such as peripheral neuropathy, closed a $30.9M Series B financing. Participants were not identified.

Qinec, Ltd.: Series B $2.5M

arubenstein — Wed, 01 May 2013 07:00:34 +0000

Qinec (United Kingdom), a Health IT company developing tools for web-based medical practice management, closed a $2.5M Series B financing. Participants include Amadeus Capital Partners and Archimedia Investments.

Biophytis, SAS: Series B $2.6M

arubenstein — Wed, 01 May 2013 07:00:26 +0000

Biophyti (France), a clinical stage pharmaceutical company developing a portfolio of nutraceuticals and drug candidates derived from active natural substances to treat metabolic disorders and age related diseases, closed a $2.6M Series B financing. Participants include Metabrain Research, Seventure Partners and CM-CIC Capital Prive.

Innovent Biologics, Inc.: Series B $25M

arubenstein — Tue, 30 Apr 2013 07:00:47 +0000

Innovent Biologics (China), a clinical stage biotechnology company focused on the development of monoclonal antibodies targeting various diseases, closed a $25M Series B financing. Participants include Lilly Asia Ventures, Fidelity Biosciences and Fidelity Growth Partners Asia.

Cardioxyl Pharmaceuticals, Inc.: Series B $28M

arubenstein — Tue, 30 Apr 2013 07:00:00 +0000

Cardioxyl Pharmaceuticals (Chapel Hill, NC), a clinical stage pharmaceutical company utilizing its proprietary nitroxyl chemistry platform to discover and develop novel therapeutics to treat cardiovascular disease, closed a $28M Series B financing. Participants include OrbiMed Advisors, Osage University Partners, New Enterprise Associates and The Aurora Funds.

Intarcia Therapeutics, Inc.: Series C $160M

arubenstein — Mon, 29 Apr 2013 02:48:33 +0000

Intarcia Therapeutics (Hayward, CA), a clinical stage medical device company focused on developing a subcutaneous device to continuously deliver diabetes therapeutic exenatide, closed a $160M Series C financing, in addition to a $50M debt financing, totaling $210M for the round. Participants include New Enterprise Associates, New Leaf Venture Partners, Venrock, The Baupost Group, and Farallon Capital Management.